Review Article
Gastrointestinal Cytoprotection by PPARγ Ligands

Yuji Naito, Tomohisa Takagi, and Toshikazu Yoshikawa

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan

Correspondence should be addressed to Yuji Naito, ynaito@koto.kpu-m.ac.jp

Received 29 April 2010; Accepted 23 August 2010

Academic Editor: Paul Drew

Copyright © 2010 Yuji Naito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that is known to play a central role in lipid metabolism and insulin sensitivity as well as inflammation and cell proliferation. According to the results obtained from studies on several animal models of gastrointestinal inflammation, PPARγ has been implicated in the regulation of the immune response, particularly inflammation control, and has gained importance as a potential therapeutic target in the management of gastrointestinal inflammation. In the present paper, we present the current knowledge on the role of PPARγ ligands in the gastrointestinal tract.

1. Introduction

Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily and have been initially described as molecular targets for compounds that cause peroxisome proliferation [1]. Thus far, 3 isotypes of PPARs (PPARα, PPARβ (also known as PPARδ), and PPARγ) have been found in various species [2–5]. Of these, PPARγ proved to be a key transcription factor involved in lipid metabolism and adipocyte differentiation. In addition, recent studies suggest that PPARγ may be involved in the control of inflammation and especially modulation of the expression of various cytokines in monocytes and macrophages [6, 7]. Regarding the anti-inflammatory properties of PPARγ, PPARγ activation has been shown to antagonize the activity of activation protein-1 (AP-1), Stat 1, and nuclear factor-κB (NF-κB), which are known for positively controlling cytokine gene expression [6].

PPARγ predominates the adipose tissue, large intestine, macrophages, and monocytes [6, 8–10]. Recently, it was demonstrated that 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), and various polyunsaturated fatty acids have been identified as natural receptor ligands of PPARγ. In addition, thiazolidinediones such as troglitazone, pioglitazone, and rosiglitazone, which are used as antidiabetic drugs, have been developed as synthetic PPARγ ligands. The use of such ligands has allowed researchers to unveil many potential roles of PPARs in pathological conditions, including atherosclerosis, inflammation, and cancer. In this paper, we present the current knowledge available on the role of PPARγ in the gastrointestinal tract.

2. Esophagus and PPARγ

Few studies have examined the role of PPARγ in the esophageal mucosa. PPARγ expression in the epithelium of Barrett’s esophagus (BE) is elevated as compared to that in the normal esophageal squamous epithelium [11]. Reflux of gastric juice or bile acid into the esophagus causes injury to the esophageal squamous epithelium, because of which the injured esophageal mucosa is replaced by columnar epithelium; this entity is called BE. Importantly, BE is the major risk factor for esophageal adenocarcinoma. The PPARγ ligands pioglitazone and ciglitazone when used alone inhibited cell proliferation in OE33 cells derived from esophageal adenocarcinoma [11, 12]; this result suggests that PPARγ plays an important role in Barrett’s carcinogenesis and that PPARγ ligands may be useful as new therapeutic agents for the prevention and treatment of Barrett’s carcinoma. However, because it has been reported that OE33-derived transplantable adenocarcinoma was enhanced in vivo by systemic PPARγ activation due to cell proliferation, the detailed role of PPARγ in the esophagus remains controversial [11].
In regard to human esophageal squamous cell carcinoma (SCC), PPARγ has been found to be expressed in human SCC cell lines such as TE-1, TE-2, TE-5, TE-7, TE-8, TE-9, and TE-10 [13, 14]. Interestingly, PPARγ ligands such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), and troglitazone significantly inhibited the proliferation of these SCC cells in a dose-dependent manner [13]. On the other hand, Terashita et al. reported that although PPARγ mRNA expression was detectable in the majority of human SCC tissues and all the normal esophageal mucosa, PPARγ mRNA expression level was significantly decreased in SCC tissues compared to normal esophageal mucosa [14]. In their clinicopathological studies, PPARγ expression was detectable in the majority of human SCC tissues and all the normal esophageal mucosa, PPARγ expression level was significantly decreased compared with those with less extensive lymph node metastasis. Thus, the role of PPARγ remains controversial in esophageal SCC as well as esophageal adenocarcinoma, and further examinations is required to gain a better understanding of the role of PPARγ in esophageal tumors.

### 3. Stomach and PPARγ

In several studies, it has been demonstrated that PPARγ ligands reduced the extent of mucosal damage and inhibited the inflammatory response to gastric inflammation (Table 1). First, we demonstrated that pioglitazone, a specific PPARγ ligand, ameliorated aspirin-induced injury to the gastric mucosa in rats (Figure 1) and inhibited the increase in neutrophil accumulation associated with gastric mucosal TNF-α contents, which were measured by Enzyme-Linked Immunosorbent Assay (ELISA) [15]. PPARγ has also been implicated in the control of gastric mucosal damage induced by ischemia-reperfusion injury [16]. Pioglitazone, rosiglitazone, troglitazone, and 15d-PGJ2 inhibited gastric mucosal damage induced by ischemia-reperfusion injury through the inhibition of cytokines expression such as TNF-α and IL-1β, and the inhibition of the neutrophil accumulation in the gastric mucosa [16–21]. Interestingly, regarding the expression of intercellular adhesion molecule-1 (ICAM-1), which played an important role in neutrophil infiltration into gastric mucosa, the increased expression of ICAM-1 after gastric ischemia reperfusion was also inhibited by treatment with these PPARγ ligands [18, 21]. Thus, PPARγ mediated the amelioration of the inflammatory responses involved in acute gastric damage.

In gastric ulcer healing, it seems that the activation of PPARγ ligands produces favorable effects. Pioglitazone accelerates the healing of acetic acid-induced gastric ulcers by the triggering anti-inflammatory effects, including the suppression of interleukin (IL)-1β, tumor necrosis factor-α (TNF-α), cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS), and by increasing the expression of heat shock protein 70 (HSP70) [23]. Brzozowski et al. also demonstrated that pioglitazone accelerates the healing of gastric ulcers induced by topical application of 100% ethanol or water immersion and restraint stress [24]. In addition to suppression of the proinflammatory cytokines TNF-α and interleukin-1β (IL-1β, pioglitazone enhanced angiogenesis through increased expression of platelet endothelial cell adhesion molecule-1 (PECAM-1)). Furthermore, Lahiri et al. also reported that pioglitazone-induced activation of PPARγ mediated gastric ulcer healing in rats, and this pioglitazone-mediated gastroprotective effect is also involved in glucocorticoid receptor activation during chronic gastric ulcer healing [22]. Hence, together the data suggest that PPARγ is a novel therapeutic target molecule and PPARγ ligands can be used as therapeutic agents for gastric ulcerative lesion.

Interestingly, PPARγ plays a crucial role in gastric mucosal injury in relation to *H. pylori* (*Helicobacter pylori*) infection. As it has been well known that *Helicobacter pylori* infection plays important role as the cause of chronic gastritis [37] and as a definite carcinogen in gastric cancer [38], understanding how PPARγ is involved in *H. pylori* infection may lead to the development of therapeutic strategy for *H. pylori* infection. B. L. Slomiany and A. Slomiany have demonstrated that *H. pylori* lipopolysaccharide (LPS-) elicited mucosal inflammatory responses were accompanied by a massive epithelial cell apoptosis, upregulation of iNOS, and COX-2 expression, and PPARγ ligand ciglitazone suppresses these gastric mucosal inflammatory responses and may provide therapeutic benefits such as the amelioration of inflammation associated with *H. pylori* infection [39]. In fact, PPARγ expression in the gastric mucosa increases with *H. pylori* infection and produces cytoprotective and anti-inflammatory effects in the gastric mucosa [40]. Furthermore, Konturek et al. also have shown that PPARγ is implicated in *H. pylori*-related gastric carcinogenesis and that PPARγ agonists may have a therapeutic role in cancer [41]. On experimental investigation, it was found that PPARγ suppresses gastric carcinogenesis and that PPARγ ligands such as troglitazone and ciglitazone are potential agents for

### Table 1: Cytoprotective properties of PPARγ in experimental model of gastric injuries.

| Model                      | PPARγ ligand | References       |
|----------------------------|--------------|------------------|
| Gastric Ulcer              |              |                  |
| (Acute gastric damage)     | Pioglitazone | Naito et al. [15]|
| (H. pylori-induced gastritis) | Citiglitazone | B. L. Slomiany and A. Slomiany [39]|
| (Gastric ulcer Healing)    | Pioglitazone | Konturek et al. [17], Brzozowski et al. [24], Lahiri et al. [22]|
| Ischemia-reperfusion       | Pioglitazone | Ichikawa et al. [16], Konturek et al. [23], Wada et al. [21]|
| Rosiglitazone             |             | Wada et al. [21]|
| Troglitazone              |             | Wada et al. [21]|
| 15d-PGJ2                  |             | Takagi et al. [19]|

**PPAR Research**
gastric carcinoma because they inhibit PPARγ-dependant cell proliferation [42–44].

On the other hand, the importance of PPARγ polymorphism (Pro12Ala) has been reported. The PPARγ Pro12Ala polymorphism has been reported to show decreased binding to the promoter element and demonstrates weaker transactivation of responsive promoters [45]. It has been reported that PPARγ polymorphism (Pro12Ala) is associated with various disease including diabetes, asthma, endometriosis, polycystic ovary, and colorectal cancer [46–50]. Regarding to gastric disease, this PPARγ polymorphism is associated with not only gastric ulcer but also gastric adenocarcinoma [51–53].

4. Intestine and PPARγ

In many studies, PPARγ has been reported to play a role in the small and large intestine. This is probably because of high PPARγ expression in the colon tissue. The high expression of PPARγ seems to be related to intestinal bacteria. Dubuquoy et al. showed that PPARγ expression in the colon tissue was greater in conventional mice than in germ-free mice [54]. More interestingly, they demonstrated that PPARγ expression was weaker in the colon tissue of mice deleted for the Toll-like receptor (TLR4) than in that of wild-type mice. Furthermore, in colonic epithelial cells such as HT-29 and Caco-2, PPARγ expression was markedly increased because
Figure 2: (a) Image showing the appearance of the colon in a mouse that was administered dextran sulfate sodium (DSS) (i) and pioglitazone (ii). Loss and shortening of crypts, mucosal erosions, inflammatory cell infiltration, and goblet cell depletion are seen in (i). In (ii), smaller erosions are associated with less inflammatory cell infiltration. Hematoxylin and eosin staining, ×10.

(b) Reverse transcriptase-polymerase chain reaction (RT-PCR) of TNF-α (276 bp).

(c) Electrophoresis mobility shift assay (EMSA) of NF-κB.

Table 2: Cytoprotective properties of PPARγ in experimental model of the intestinal inflammation.

| Model                      | PPARγ ligand | References                        |
|----------------------------|--------------|-----------------------------------|
| Ischemia/reperfusion injury| Rosiglitazone| Nakajima et al. [18]              |
|                            | Pioglitazone | Naito et al. [25]                 |
|                            | 15d-PGJ2     | Cuzzocrea et al. [26]             |
| DSS colitis                | Troglitazone | Su et al. [27]                    |
|                            | Rosiglitazone| Sáubemann et al. [28]            |
|                            | Pioglitazone | Takagi et al. [29], Schaefer et al. [30] |
|                            | CLA          | Bassaganya-Riera et al. [31]     |
| TNBS colitis               | Troglitazone | Desreumiaux et al. [32]           |
|                            | Rosiglitazone| Sánchez-Hidalgo et al. [33]       |
|                            | Pioglitazone | Schaefer et al. [30]             |
|                            | 5-ASA        | Rousseaux et al. [34]            |
| CD4+CD45RBhigh (transfer colitis model) | CLA | Bassaganya-Riera et al. [31] |
| IL-10 KO (genetic colitis model) | Rosiglitazone | Lytle et al. [35]               |
| SAMP1/YitFC (spontaneous colitis model) | Rosiglitazone | Sugawara et al. [36]            |

DSS, dextran sodium sulphate; TNBS, 2,4,6-trinitrobenzene sulfonic acid; 15dPGJ2, 15-deoxy-D12,14-prostaglandin J2; CLA, conjugated linoleic acid; 5-ASA, 5-aminosalicylic acid; IL-10 KO, interleukin 10 knockout mice.

of the presence of LPSs [55]. These data indicate that the role of bacteria-derived LPS in the regulation of PPAR expression is more crucial in the colon tissue than in other parts of the gastrointestinal tract.

With regard to the anti-inflammatory properties of P PPARγ in intestinal inflammation, the therapeutic efficacy of PPARγ ligands has been evaluated in various different models of intestinal inflammation (Table 2). To determine the role of PPARγ in intestinal ischemia-reperfusion injury, Nakajima et al. [18] used PPARγ-deficient mice and the PPARγ agonist rosiglitazone. They demonstrated the dramatic protective effects of rosiglitazone on both local and remote organ injury after intestinal ischemia-reperfusion injury and showed that the endogenous absence of PPARγ leads to aggravated injury in this model. In several studies, it has been demonstrated that the activation of PPARγ by PPARγ ligands inhibited intestinal ischemia-reperfusion injury [25, 26, 56]. One possible mechanism by which PPARγ activation helps in protection against ischemia-reperfusion...
Injury is through the inhibition of NF-κB-mediated transcription. The inhibition of NF-κB activation was confirmed by several approaches, including electrophoretic mobility shift assays, immunohistochemistry using a phosphorylation state-specific antibody for IκB, and mRNA levels of TNF-α and intercellular adhesion molecule-1 (ICAM-1), which are downstream targets of NF-κB.

Inflammatory bowel diseases (IBDs) such as ulcerative colitis (UC) and Crohn’s disease (CD) constitute chronic and recurrent intestinal inflammatory disorders; the precise pathogenesis of these disorders remains unknown [57]. Therefore, it is very important to identify novel therapeutic molecules for IBDs. In this regard, PPARγ may be a novel therapeutic target. Su et al. showed that PPARγ ligands markedly reduced colonic inflammation in a mouse model of IBD [27]. We also reported that pioglitazone had a protective effect against murine dextran sulfate sodium- (DSS-) induced colitis; a model of colitis induced in this manner is commonly used as a UC model in association with inhibition of the NF-κB-cytokine cascade [29] (Figure 2). In mice, overexpression of PPARγ by an adenoviral construct in mucosal epithelial cells was associated with amelioration of experimental inflammation [58], and this study supports the hypothesis that the upregulation of PPARγ expression itself may have a protective effect against colitis. In another study, in which colitis was induced by trinitrobenzene sulfonic acid (TNBS) and used as a UC model, PPARγ knockout mice were refractory to 5-ASA treatment, and 5-ASA directly inhibited the development of the intestinal inflammation [60]. In this paper, we focused on the therapeutic effects produced in the colon.

PPARγ agonists may represent a new group of biological agents that inhibit the secretion of molecules that would end up promoting tumor growth. Osawa et al. recently showed that continuous feeding of pioglitazone reduced the aberrant crypt foci formation and notably suppressed colon tumors in the APCmin/+ mice showed an increased number of polyps when subjected to a PPARγ agonist [65]. Although there is a contradictory study in which APCmin/+ mice showed an increased number of polyps when subjected to a PPARγ agonist [66], many research studies have shown that PPARγ agonists seem to have inhibitory effects on the proliferation of colon cancer cells. PPARγ ligands may represent a new group of biological agents that can be used for the management of colon cancer.

5. Conclusion

In this paper, we focused on the therapeutic effect of PPARγ agonists in gastrointestinal inflammation. We performed studies using several animal models of gastrointestinal inflammation and accumulated evidence suggesting that PPARγ plays a crucial role in gastrointestinal inflammation. It was found that PPARγ ligand therapy reduced a wide variety of inflammatory indices in different animal models, but the underlying mechanism by which PPARγ activation produces these effects was not fully established. We expect
that the precise mechanism by which PPARγ ligands produce anti-inflammatory properties will be clarified in the near future.

References

[1] D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor superfamily: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.
[2] T. Sher, H.-F. Yi, O. W. McBride, and F. J. Gonzalez, “cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor,” Biochemistry, vol. 32, no. 21, pp. 5598–5604, 1993.
[3] A. Schmidt, N. Endo, S. J. Rutledge, C. A. Cullinan, and G. A. Rodan, “Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids,” Molecular Endocrinology, vol. 6, no. 10, pp. 1634–1641, 1992.
[4] A. Elbrecht, Y. Chen, C. A. Cullinan et al., “Molecular cloning, expression and characterization of human peroxisome proliferator activated receptor α1 and y2,” Biochemical and Biophysical Research Communications, vol. 224, no. 2, pp. 431–437, 1996.
[5] L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18879, 1997.
[6] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998.
[7] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
[8] D. Auboeuf, J. Rieuze, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.
[9] N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998.
[10] R. Mukherjee, L. Jow, D. Noonan, and D. P. McDonnell, “Human and rat peroxisome proliferator-activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators,” Journal of Steroid Biochemistry and Molecular Biology, vol. 51, no. 3–4, pp. 157–166, 1994.
[11] O. H. Al-Taie, T. Graf, B. Illert et al., “Differential effects of PPARγ activation by the oral antidiabetic agent pioglitazone in Barrett’s carcinoma in vitro and in vivo,” Journal of Gastroenterology, vol. 44, no. 9, pp. 919–929, 2009.
[12] P. C. Konturek, A. Nikiforuk, J. Kania, M. Raithel, E. G. Hahn, and S. M. Mühl dorfer, “Activation of NFκB represents the central event in the neoplastic progression associated with Barrett’s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARγ and growth factors,” Digestive Diseases and Sciences, vol. 49, no. 7–8, pp. 1075–1083, 2004.
[13] T. Takashima, Y. Fujiwara, M. Hamaguchi et al., “Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma,” Oncology Reports, vol. 13, no. 4, pp. 601–606, 2005.
[14] Y. Terashita, H. Sasaki, N. Haruki et al., “Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer,” Japanese Journal of Clinical Oncology, vol. 32, no. 7, pp. 238–243, 2002.
[15] Y. Naito, T. Takagi, K. Matsuyama, N. Yoshida, and T. Yoshikawa, “Pioglitazone, a specific PPAR-γ ligand, inhibits aspirin-induced gastric mucosal injury in rats,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 6, pp. 865–873, 2001.
[16] H. Ichikawa, Y. Naito, T. Takagi, N. Tomatsuri, N. Yoshida, and T. Yoshikawa, “A specific peroxisome proliferator-induced receptor-γ (PPAR-γ) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats,” Redox Report, vol. 7, no. 5, pp. 343–346, 2002.
[17] C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998.
[18] D. Auboeuf, J. Rieuze, L. Fajas et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.
[19] N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells,” Circulation Research, vol. 83, no. 11, pp. 1097–1103, 1998.
[20] R. Mukherjee, L. Jow, D. Noonan, and D. P. McDonnell, “Human and rat peroxisome proliferator-activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators,” Journal of Steroid Biochemistry and Molecular Biology, vol. 51, no. 3–4, pp. 157–166, 1994.
[21] O. H. Al-Taie, T. Graf, B. Illert et al., “Differential effects of PPARγ activation by the oral antidiabetic agent pioglitazone in Barrett’s carcinoma in vitro and in vivo,” Journal of Gastroenterology, vol. 44, no. 9, pp. 919–929, 2009.
[22] P. C. Konturek, A. Nikiforuk, J. Kania, M. Raithel, E. G. Hahn, and S. M. Mühl dorfer, “Activation of NFκB represents the central event in the neoplastic progression associated with Barrett’s esophagus: a possible link to the inflammation and overexpression of COX-2, PPARγ and growth factors,” Digestive Diseases and Sciences, vol. 49, no. 7–8, pp. 1075–1083, 2004.
[23] T. Takashima, Y. Fujiwara, M. Hamaguchi et al., “Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma,” Oncology Reports, vol. 13, no. 4, pp. 601–606, 2005.
[27] C. G. Su, X. Wen, S. T. Bailey et al., “A novel therapy for colitis utilizing PPAR-y ligands to inhibit the epithelial inflammatory response,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999.

[28] L. J. Saubermann, A. Nakajima, K. Wada et al., “Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis,” Inflammatory Bowel Diseases, vol. 8, no. 5, pp. 330–339, 2002.

[29] T. Takagi, Y. Naito, N. Tomatsuri et al., “Pioglitazone, a PPAR-y ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kB-cytokine cascade,” Redox Report, vol. 7, no. 5, pp. 283–289, 2002.

[30] K. L. Schaefer, S. Denevich, C. Ma et al., “Intestinal antiinflammatory effects of thiazolidinedione peroxisome proliferator-activated receptor-y ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms,” Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 244–252, 2005.

[31] J. Bassaganya-Riera, K. Reynolds, S. Martino-Catt et al., “Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease,” Gastroenterology, vol. 127, no. 3, pp. 777–791, 2004.

[32] P. Desreumaux, L. Dubuquoy, S. Nutten et al., “Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer: a basis for new therapeutic strategies,” Journal of Experimental Medicine, vol. 193, no. 7, pp. 827–838, 2001.

[33] M. Sánchez-Hidalgo, A. R. Martín, I. Villegas, and C. Alarón de la Lastra, “Rosiglitazone, a PPARγ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats,” European Journal of Pharmacology, vol. 562, no. 3, pp. 247–258, 2007.

[34] C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ,” Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005.

[35] C. Lytle, T. J. Tod, K. T. Vos, J. W. Lee, R. D. Atkinson, and D. S. Straus, “The peroxisome proliferator-activated receptor γ ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency,” Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 231–243, 2005.

[36] K. Sugawara, T. S. Olson, C. A. Moskaluk et al., “Linkage to peroxisome proliferator-activated receptor-γ in SAMP1/YitFc mice and in human Crohn’s disease,” Gastroenterology, vol. 128, no. 2, pp. 351–360, 2005.

[37] B. J. Marshall and J. R. Warren, “Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration,” Lancet, vol. 1, no. 8390, pp. 1311–1314, 1984.

[38] International Agency for Research on Cancer WHO, “Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans,” IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 61, pp. 1–241, 1994.

[39] B. L. Slomiany and A. Slomiany, “Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor γ activation,” JUBMB Life, vol. 53, no. 6, pp. 303–308, 2002.

[40] H. Haruna, T. Shimizu, Y. Ohtsuka et al., “Expression of COX-1, COX-2, and PPAR-y in the gastric mucosa of children with Helicobacter pylori infection,” Pediatrics International, vol. 50, no. 1, pp. 1–6, 2008.

[41] P. C. Konturek, J. Kania, V. Kukharsky et al., “Implication of peroxisome proliferator-activated receptor y and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection,” Journal of Pharmaceutical Sciences, vol. 96, no. 2, pp. 134–143, 2004.

[42] C. W. Cheon, D. H. Kim, D. H. Kim, Y. H. Cho, and J. H. Kim, “Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells,” World Journal of Gastroenterology, vol. 15, no. 3, pp. 310–320, 2009.

[43] J. Lu, K. Imamura, S. Nomura et al., “Chemopreventive effect of peroxisome proliferator-activated receptor y on gastric carcinogenesis in mice,” Cancer Research, vol. 65, no. 11, pp. 4769–4774, 2005.

[44] M. Nagamine, T. Okumura, S. Tanno et al., “PPARY ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells,” Cancer Science, vol. 94, no. 4, pp. 338–343, 2003.

[45] S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998.

[46] S. Landi, V. Moreno, L. Gioia-Paticola et al., “Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor α, NFKB1, and peroxisome proliferator-activated receptor γ with colorectal cancer,” Cancer Research, vol. 63, no. 13, pp. 3560–3566, 2003.

[47] D. Althuiler, J. N. Hirschhorn, M. Klannemark et al., “The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes,” Nature Genetics, vol. 26, no. 1, pp. 76–80, 2000.

[48] S. J. Chae, J. J. Kim, Y. M. Choi, J. M. Kim, Y. M. Cho, and S. Y. Moon, “Peroxisome proliferator-activated receptor-γ and its coactivator-1α gene polymorphisms in Korean women with polycystic ovary syndrome,” Gynecologic and Obstetric Investigation, vol. 70, no. 1, pp. 1–7, 2010.

[49] S.-H. Oh, S.-M. Park, J.-S. Park et al., “Association analysis of peroxisome proliferator-activated receptors gamma gene polymorphisms with aspirin hypersensitivity in asthmatics,” Allergy, Asthma and Immunology Research, vol. 1, no. 1, pp. 30–35, 2009.

[50] K. R. Hwang, Y. M. Choi, J. M. Kim et al., “Association of peroxisome proliferator-activated receptor-γ 2 Pro12Ala polymorphism with advanced-stage endometriosis,” American Journal of Reproductive Immunology. In press.

[51] S.-Y. Liao, Z.-R. Zeng, W. K. Leung et al., “Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 2, pp. 289–294, 2006.

[52] K. N. Prasad, A. Saxena, U. C. Ghoshal, M. R. Bhagat, and N. Krishnani, “Analysis of Pro12Ala PPAR γ gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease,” Annals of Oncology, vol. 19, no. 7, pp. 1298–1303, 2008.

[53] T. Tahara, T. Arisawa, T. Shibata et al., “Influence of peroxisome proliferator-activated receptor (PPAR)γ Plo12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese,” Digestive Diseases and Sciences, vol. 53, no. 3, pp. 614–621, 2008.

[54] L. Dubuquoy, E. A. Jansson, S. Deeb et al., “Impaired expression of peroxisome proliferator-activated receptor y in ulcerative colitis,” Gastroenterology, vol. 124, no. 5, pp. 1265–1276, 2003.
[55] S. E. Chang, S. H. Dong, H. L. Seung et al., “Attenuation of colonic inflammation by PPARγ in intestinal epithelial cells: effect on toll-like receptor pathway,” Digestive Diseases and Sciences, vol. 51, no. 4, pp. 693–697, 2006.

[56] N. Baregamian, J. M. Mourot, A. R. Ballard, B. M. Evers, and D. H. Chung, “PPAR-γ agonist protects against intestinal injury during necrotizing enterocolitis,” Biochemical and Biophysical Research Communications, vol. 379, no. 2, pp. 423–427, 2009.

[57] R. J. Xavier and D. K. Podolsky, “Unravelling the pathogenesis of inflammatory bowel disease,” Nature, vol. 448, no. 7152, pp. 427–434, 2007.

[58] K. Katayama, K. Wada, A. Nakajima et al., “A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model,” Gastroenterology, vol. 124, no. 5, pp. 1315–1324, 2003.

[59] L. Klotz, I. Dani, F. Edenhofer et al., “Peroxisome proliferator-activated receptor γ control of dendritic cell function contributes to development of CD4+ T cell anergy,” Journal of Immunology, vol. 178, no. 4, pp. 2122–2131, 2007.

[60] R. Hontecillas and J. Bassaganya-Riera, “Peroxisome proliferator-activated receptor γ is required for regulatory CD4+ T cell-mediated protection against colitis,” Journal of Immunology, vol. 178, no. 5, pp. 2940–2949, 2007.

[61] J. D. Lewis, G. R. Lichtenstein, R. B. Stein et al., “An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis,” American Journal of Gastroenterology, vol. 96, no. 12, pp. 3323–3328, 2001.

[62] R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, “The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers,” Carcinogenesis, vol. 19, no. 1, pp. 49–53, 1998.

[63] P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPARγ,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998.

[64] W.-L. Yang and H. Frucht, “Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells,” Carcinogenesis, vol. 22, no. 9, pp. 1379–1383, 2001.

[65] E. Osawa, A. Nakajima, K. Wada et al., “Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice,” Gastroenterology, vol. 124, no. 2, pp. 361–367, 2003.

[66] A.-M. Lefebvre, I. Chen, P. Desreumaux et al., “Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC(Min)/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998.